Acomplia (rimonabant)
- Region
- 🇪🇺 EU
- Active substance
- rimonabant
- Company
- sanofi-aventis
- Status
- Withdrawn
- Therapeutic area
- Obesity
- EU approval
- Mon 19 Jun 2006
- Application
- EMEA/H/C/000666
- ATC
- A08AX01
- Official record
- www.ema.europa.eu
Indication
As an adjunct to diet and exercise for the treatment of obese patients (BMI 30 kg/m2), or overweight patients (BMI 27 kg/m2) with associated risk factor(s), such as type 2 diabetes or dyslipidaemia (see section 5.1).
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Zimulti Withdrawn · sanofi-aventis
Follow Acomplia
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.